CartiHeal Announces First Commercial Implantation of Agili-C™ in the US
Comunicato Precedente
Comunicato Successivo
Dr. Zaslav commented, "Agili-C is a technology I and others in the surgical community have been watching and waiting on for over 10 years. It is a novel implant supported by 4-years of data and counting from the multinational, randomized and controlled IDE clinical trial. Agili-C offers a cost efficient, off-the-shelf implant to fill an unmet need in my clinical practice."
"We are thrilled to share the Agili-C technology with the surgical community with a goal for it to reach every surgical facility in the US and beyond," said Nir Altschuler, CartiHeal's Founder and CEO. "This is a milestone achievement for everyone at CartiHeal and we would like to congratulate Dr. Zaslav on successfully performing our first commercial case in the US."
Agili-C is available nationwide.
About CartiHeal
CartiHeal is an Israel and New Jersey based, privately held medical device company focused on the design, development, and commercialization of proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
Prescribing information
The Agili-C™ scaffold is indicated for the treatment of an International Cartilage Repair Society grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2, without severe osteoarthritis (Kellgren-Lawrence grade 0-3).
For more information
www.cartiheal.com
Media contact:
Lizet Shilo
info@cartiheal.com
Photo - https://mma.prnewswire.com/media/2162498/Dr_Ken_Zaslav_Headshot.jpg
Logo - https://mma.prnewswire.com/media/1776650/CartiHeal_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cartiheal-announces-first-commercial-implantation-of-agili-c-in-the-us-301886297.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
